The University of Southampton
University of Southampton Institutional Repository

Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma

Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
This study investigated the effect of low dose of budesonide 100 ?g b.d from a new multi-dose dry powder inhaler (Airmax™) and from a conventional inhaler (Turbuhaler®) on bronchial hyper-responsiveness, lung function and asthma symptoms in mild stable asthmatics. Twenty-five patients were enrolled into a double-blind double-dummy crossover study with two 4-week treatment periods separated by a 4-week washout. Patients had a mean forced expiratory volume in 1 s (FEV?) of 91±13% predicted, had previously received inhaled short-acting ??-agonists only and had a PC?? to adenosine 5? monophosphate (AMP)<40 mg/ml. PC?? AMP was assessed at baseline, and at the start and end of each treatment period. Patients recorded peak expiratory flow and symptoms throughout the study. There was a mean increase in PC??AMP from start to end of 3.49 doubling dilutions (DD) in the Airmax™ group and 2.90 DD in the Turbuhaler® group. The difference was 0.60 DD(95% CI—0.47, 1.69) favouring Airmax™ and the upper limit exceeded the equivalence limit of ±1 DD. There were similar improvements in FEV?, daily PEF and symptoms in both groups. The majority of patients preferred treatment with Airmax™ to Turbuhaler® (64 vs. 23%). Both treatments were equally well tolerated. In conclusion, 100 ?g budesonide bid during 4 weeks from AirmaxTM effectively attenuates the response to AMP in mild asthmatics. Overall Airmax™ offers equal clinical benefit to Turbuhaler® and is preferred by patients.
dry powder inhaler, FEV?, adenosine 5?-monophosphate, airway hyper-reactivity, inflammation, clinical trial
542-547
Frew, A.J.
c00e9630-a5f0-44b3-add0-44b68836bbcb
Langley, S.J.
939fa822-cec0-44ed-8cca-f56d0c680a86
Perrin, V.
e880c25e-5223-4397-9b61-f6d950a28e1a
Hertog, M.G.L.
3f70a5cb-57f6-4a8d-944f-d9357d5ba604
Frew, A.J.
c00e9630-a5f0-44b3-add0-44b68836bbcb
Langley, S.J.
939fa822-cec0-44ed-8cca-f56d0c680a86
Perrin, V.
e880c25e-5223-4397-9b61-f6d950a28e1a
Hertog, M.G.L.
3f70a5cb-57f6-4a8d-944f-d9357d5ba604

Frew, A.J., Langley, S.J., Perrin, V. and Hertog, M.G.L. (2002) Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma. Respiratory Medicine, 96 (7), 542-547. (doi:10.1053/rmed.2002.1290).

Record type: Article

Abstract

This study investigated the effect of low dose of budesonide 100 ?g b.d from a new multi-dose dry powder inhaler (Airmax™) and from a conventional inhaler (Turbuhaler®) on bronchial hyper-responsiveness, lung function and asthma symptoms in mild stable asthmatics. Twenty-five patients were enrolled into a double-blind double-dummy crossover study with two 4-week treatment periods separated by a 4-week washout. Patients had a mean forced expiratory volume in 1 s (FEV?) of 91±13% predicted, had previously received inhaled short-acting ??-agonists only and had a PC?? to adenosine 5? monophosphate (AMP)<40 mg/ml. PC?? AMP was assessed at baseline, and at the start and end of each treatment period. Patients recorded peak expiratory flow and symptoms throughout the study. There was a mean increase in PC??AMP from start to end of 3.49 doubling dilutions (DD) in the Airmax™ group and 2.90 DD in the Turbuhaler® group. The difference was 0.60 DD(95% CI—0.47, 1.69) favouring Airmax™ and the upper limit exceeded the equivalence limit of ±1 DD. There were similar improvements in FEV?, daily PEF and symptoms in both groups. The majority of patients preferred treatment with Airmax™ to Turbuhaler® (64 vs. 23%). Both treatments were equally well tolerated. In conclusion, 100 ?g budesonide bid during 4 weeks from AirmaxTM effectively attenuates the response to AMP in mild asthmatics. Overall Airmax™ offers equal clinical benefit to Turbuhaler® and is preferred by patients.

This record has no associated files available for download.

More information

Published date: 2002
Keywords: dry powder inhaler, FEV?, adenosine 5?-monophosphate, airway hyper-reactivity, inflammation, clinical trial

Identifiers

Local EPrints ID: 27051
URI: http://eprints.soton.ac.uk/id/eprint/27051
PURE UUID: 563ba646-367d-4cf9-a1e1-2c1da98205cc

Catalogue record

Date deposited: 26 Apr 2006
Last modified: 15 Mar 2024 07:15

Export record

Altmetrics

Contributors

Author: A.J. Frew
Author: S.J. Langley
Author: V. Perrin
Author: M.G.L. Hertog

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×